双氯西林-华法林药物相互作用:登记研究与3D球形原代人肝细胞体外研究
该研究基于丹麦登记数据,分析长期使用华法林患者在接受双氯西林或氟氯西林前后INR变化,并在3D球形原代人肝细胞中评估双氯西林对CYP酶的诱导作用。结果显示双氯西林显著降低INR,长期治疗时超过90%患者INR低于治疗窗,体外实验证实其诱导CYP3A4和CYP2C9,提示临床需警惕该相互作用。
要点
- 双氯西林短期和长期治疗均显著降低华法林患者的INR水平。
- 长期双氯西林治疗时超过90%患者INR降至2以下,血栓风险增加。
- 氟氯西林同样降低INR,但幅度小于双氯西林。
核心结论
- 双氯西林诱导CYP酶并降低华法林的临床疗效,长期治疗时效应显著加剧。
研究设计与样本
- 基于丹麦登记的前后对比研究,纳入长期使用华法林并接受双氯西林(n=1023)或氟氯西林(n=123)治疗的患者,分析INR变化。
- 体外采用3D球形原代人肝细胞模型,检测CYP酶的mRNA、蛋白和酶活性诱导。
主要发现
- 双氯西林短期治疗降低INR -0.65(95%CI:-0.57至-0.74),长期治疗降低-0.76(95%CI:-0.50至-1.02)。
- 长期双氯西林治疗后超过90%个体INR低于治疗水平(低于2)。
- 氟氯西林降低INR -0.37(95%CI:-0.14至-0.60)。
- 体外双氯西林对CYP3A4 mRNA、蛋白和酶活性的最大诱导倍数分别为4.9、2.9和2.4倍,CYP2C9 mRNA诱导1.7倍。
临床怎么用
- 华法林患者开始使用双氯西林或氟氯西林时需谨慎,尤其是长期治疗(如心内膜炎)。
- 建议加强INR监测并根据结果调整华法林剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Dicloxacillin is used to treat staphylococcal infections and we have previously shown that dicloxacillin is an inducer of cytochrome P450 enzymes (CYPs). Here, we employed a translational approach to investigate the effect of a treatment with dicloxacillin on warfarin efficacy in Danish registries. Furthermore, we assessed dicloxacillin as an inducer of CYPs in vitro. METHODS: We conducted a register-based study and analysed international normalized ratio (INR) levels in chronic warfarin users before and after short- and long-term use of dicloxacillin (n = 1023) and flucloxacillin (n = 123). Induction of CYPs were investigated in a novel liver model of 3D spheroid primary human hepatocytes at the level of mRNA, and protein and enzyme activity. RESULTS: Short- and long-term dicloxacillin treatments decreased INR levels by -0.65 (95% confidence interval [CI]: -0.57 to -0.74) and -0.76 (95% CI: -0.50 to -1.02), respectively. More than 90% of individuals experienced subtherapeutic INR levels (below 2) after long-term dicloxacillin treatment. Flucloxacillin decreased INR levels by -0.37 (95% CI: -0.14 to -0.60). In 3D spheroid primary human hepatocytes, the maximal induction of CYP3A4 mRNA, protein and enzyme activity by dicloxacillin were 4.9-, 2.9- and 2.4-fold, respectively. Dicloxacillin also induced CYP2C9 mRNA by 1.7-fold. CONCLUSION: Dicloxacillin induces CYPs and reduces the clinical efficacy of warfarin in patients. This effect is substantially exacerbated during long-term treatment with dicloxacillin. The in vitro results corroborated this drug-drug interaction and correlated to the clinical findings. Caution is warranted for warfarin patients that initiate dicloxacillin or flucloxacillin, especially for a long-term treatment of endocarditis.
引用
- Järvinen E, Dalgård Dunvald AC, Ernst MT, et al. Dicloxacillin-warfarin drug-drug interaction-A register-based study and in vitro investigations in 3D spheroid primary human hepatocytes. Br J Clin Pharmacol. 2023. PMID: 37021780. doi:10.1111/bcp.15738
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。